2023
DOI: 10.1093/eurjpc/zwad221
|View full text |Cite
|
Sign up to set email alerts
|

Individual lifetime benefit from low-dose colchicine in patients with chronic coronary artery disease

Abstract: Background and Aims Low-dose colchicine reduces cardiovascular risk in patients with coronary artery disease (CAD), but absolute benefits may vary between individuals. This study aimed to assess the range of absolute benefit from low-dose colchicine according to individual patient risk profile. Methods The ESC guideline-recommended SMART-REACH model was combined with the relative treatment effect of low-dose colchicine, and a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 36 publications
0
1
0
Order By: Relevance
“… 16–18 Recent clinical studies have confirmed that anti-inflammatory drugs can reduce the residual risk of cardiovascular events. 19 Moreover, the Food and Drug Administration (FDA) approval of colchicine for use in patients with coronary heart diseases has further clarified that inflammation may be a valuable predictor.…”
Section: Introductionmentioning
confidence: 99%
“… 16–18 Recent clinical studies have confirmed that anti-inflammatory drugs can reduce the residual risk of cardiovascular events. 19 Moreover, the Food and Drug Administration (FDA) approval of colchicine for use in patients with coronary heart diseases has further clarified that inflammation may be a valuable predictor.…”
Section: Introductionmentioning
confidence: 99%